Phase 2
HLX-1502
Phase 2 registry
Since , the date of the source that reports this phase.
Summary
HLX-1502 is a program from Healx. It is being developed for neurofibromatosis type 1. ClinicalTrials.gov lists it at Phase 2 (recruiting) under NCT06541847. The AI role named in the source is drug repurposing. Registry records: NCT06541847, Phase 2, recruiting, updated Jul 29, 2026. The latest dated source is from Feb 24, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Healx
- Indication
- Neurofibromatosis type 1
- Therapeutic area
- Rare disease
- AI role
- Drug repurposing
- Phase in the source
- Phase 2, as of Jul 27, 2026
- Phase source
- Registry
- Board column
- Phase 2
AI evidence
AI source: Company
“HLX-1502 was discovered using Healx’s proprietary AI platform, which accelerates the identification of potential drug candidates.”
Trial records
- NCT06541847 on ClinicalTrials.gov (opens in new tab) Phase 2 Recruiting Updated
Milestone timeline
-
Official X post: Phase 2
-
NCT06541847 record updated
Phase 2, Recruiting
Spot an error? Tell me and I'll fix it.